menu
    • menu
    [{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.39000000000000001,"dosageForm":"Infusion","sponsorNew":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VEL-101","moa":"CD28","graph1":"Undisclosed","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Xenikos B.V","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dafsolimab Setaritox","moa":"CD3\/7||CD3\/CD7","graph1":"Immunology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ Xenikos B.V","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Xenikos B.V"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Thrombomodulin Alfa","moa":"F2a","graph1":"Neurology","graph2":"Phase II","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Veloxis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veloxis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Thrombomodulin Alfa","moa":"F2a","graph1":"Neurology","graph2":"Phase II","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Veloxis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veloxis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Cedars-Sinai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Veloxis Pharmaceuticals

    Menu

    Veloxis Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Recipient : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

                            Details : Tacrolimus is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 30, 2024

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Recipient : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Guard,Dafsolimab Setaritox

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Xenikos B.V

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study E...

                            Details : T-Guard (ricin toxin A conjugated mAB) is designed to reset the body's immune system in life-threatening T cell‒mediated conditions, potentially including prevention of transplant-related rejection, treatment of acute solid-organ rejection, and severe ...

                            Product Name : T-Guard

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            June 28, 2022

                            Lead Product(s) : T-Guard,Dafsolimab Setaritox

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Xenikos B.V

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FR104

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Asahi Kasei Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Inves...

                            Details : VEL-101 (FR104) is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 18, 2022

                            Lead Product(s) : FR104

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Asahi Kasei Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FR104

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : OSE Immunotherapeutics SA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel ...

                            Details : VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 18, 2022

                            Lead Product(s) : FR104

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : OSE Immunotherapeutics SA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombomodulin Alfa

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

                            Details : Thrombomodulin Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Peripheral Nervous System Diseases.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 23, 2022

                            Lead Product(s) : Thrombomodulin Alfa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VEL-101

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-10...

                            Details : VEL-101 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 14, 2022

                            Lead Product(s) : VEL-101

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Recipient : Loyola University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacroli...

                            Details : Tacrolimus is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 08, 2021

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Recipient : Loyola University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FR104

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : OSE Immunotherapeutics SA

                            Deal Size : $393.6 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture...

                            Details : The collaboration grants Veloxis worldwide rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. OSE Immunotherapeutics retains all rights to develop FR104 in autoimmune di...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $8.5 million

                            April 26, 2021

                            Lead Product(s) : FR104

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : OSE Immunotherapeutics SA

                            Deal Size : $393.6 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Recipient : Vanderbilt University Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XRâ„¢

                            Details : Envarsus XR is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 09, 2021

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Recipient : Vanderbilt University Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Veloxis Pharmaceuticals

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Recipient : University of Southern California

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

                            Details : Tacrolimus is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Transplantation.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 26, 2021

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Recipient : University of Southern California

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth